Support Component D/Vaccine Discovery, Concept to Clinic

支持成分 D/疫苗发现、概念到临床

• 批准号: 9296226
• 负责人: Margaret Juliana McElrath
• 金额: $ 9.98万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9296226
• 关键词: AIDS prevention; AIDS/HIV problem; Address; Animals; Antigens; Biotechnology; Clinic; Clinical; Clinical Trials; Data; Ensure; Fred Hutchinson Cancer Research Center; HIV Vaccine Trials Network; HIV vaccine; HIV-1 vaccine; Immunology; Knowledge; Leadership; Life; Pharmacologic Substance; Phase; Prevention Research; Research; Research Personnel; Support Groups; Testing; Vaccine Research; Vaccines; Work; base; experience; insight; research clinical testing; vaccine candidate; vaccine development

Discovery Group (VDG) aims to support this CHAVI-ID by providing insight and guidance to adjust research aims based on new findings during the life of the Center. This VDG will involve leadership from the clinical HIV vaccine field, along with key researchers with biotech, pharmaceutical and academic experience. Specifically, the VDG will provide guidance on vaccine development and administration based on personal insights and experiences in the field, and will provide data on how best to blend new outside knowledge into the research focus and aims of the CHAVI-ID, thereby ensuring the work of the Center remains at the forefront of addressing critical questions in the HIV vaccine research field. This will be accomplished by the following Specific Aims: 1. To share basic, practical knowledge about vaccine development and formulate creative strategies to advance ideas to products. 2. To provide sustained guidance to enable promising HlV-1 vaccine candidates to move forward into clinical evaluation.

Discovery Group（VDG）旨在通过提供洞察力和指导来根据中心生活期间的新发现来调整研究目标，以支持此CHAVI-ID。该VDG将涉及临床HIV疫苗领域的领导，以及具有生物技术，药物和学术经验的主要研究人员。 具体而言，VDG将根据该领域的个人见解和经验提供有关疫苗开发和管理的指导，并将提供有关如何最好地将新的外部知识与Chavi-ID的研究重点融合到Chavi-ID的目标的数据，从而确保该中心的工作仍在艾滋病毒疫苗研究领域解决关键问题的最前沿。 这将通过以下特定目的来完成： 1。分享有关疫苗开发的基本实用知识，并制定创造性策略，以推进产品的想法。 2。提供持续的指导，以使有希望的HLV-1疫苗候选者继续进行临床评估。